Related Experiment Video
Updated: Jul 16, 2026

Magnetic Adjustment of Afterload in Engineered Heart Tissues
Published on: May 5, 2020
Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects
1Cardiology Group, School of Clinical Sciences, University Clinical Departments, University of Liverpool, The Duncan Building, Daulby Street, Liverpool, L69 3GA, UK. osadchii@mail.ru
Insights
Sustained beta-adrenoreceptor activation promotes cardiac hypertrophy through various molecular pathways. While initially preserving function, further progression leads to heart failure due to calcium handling issues and fibrosis.
Area of Science:
- Cardiovascular Physiology
- Molecular Cardiology
- Pharmacology
Background:
- Cardiac hypertrophy, driven by adrenergic over-activation, is a major risk factor for cardiovascular disease.
- Understanding the mechanisms of myocardial growth and functional changes in hypertrophy is crucial.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying catecholamine-induced cardiac hypertrophy.
- To investigate the functional consequences of structural changes in hypertrophied myocardium.
Main Methods:
- Utilized an animal model of chronic systemic beta-adrenoreceptor agonist administration.
- Analyzed molecular signaling pathways including growth factors, proto-oncogenes, oxidative stress, MAPKs, and PI3K.
- Assessed cardiac autonomic regulation and beta-adrenoreceptor function.
Main Results:
- Sustained beta-adrenoreceptor activation enhances myocardial protein synthesis and promotes cardiac hypertrophy.
- Hypertrophy is associated with impaired autonomic regulation and altered beta-adrenoreceptor signaling.
- Compensated hypertrophy shows preserved systolic function via enhanced calcium handling, but progresses to heart failure due to calcium abnormalities and fibrosis.
Conclusions:
- Adrenergic over-activation is a key driver of cardiac hypertrophy with complex molecular underpinnings.
- Early stages of hypertrophy may involve compensatory mechanisms, but progression leads to functional decline and heart failure.
- Targeting these pathways may offer therapeutic strategies for managing cardiac hypertrophy and heart failure.
Abstract:
Cardiac hypertrophy is promoted by adrenergic over-activation and represents an independent risk factor for cardiovascular morbidity and mortality. The basic knowledge about mechanisms by which sustained adrenergic activation promotes myocardial growth, as well as understanding how structural changes in hypertrophied myocardium could affect myocardial function has been acquired from studies using an animal model of chronic systemic beta-adrenoreceptor agonist administration. Sustained beta-adrenoreceptor activation was shown to enhance the synthesis of myocardial proteins, an effect mediated via stimulation of myocardial growth factors, up-regulation of nuclear proto-oncogenes, induction of cardiac oxidative stress, as well as activation of mitogen-activated protein kinases and phosphatidylinositol 3-kinase. Sustained beta-adrenoreceptor activation contributes to impaired cardiac autonomic regulation as evidenced by blunted parasympathetically-mediated cardiovascular reflexes as well as abnormal storage of myocardial catecholamines. Catecholamine-induced cardiac hypertrophy is associated with reduced contractile responses to adrenergic agonists, an effect attributed to downregulation of myocardial beta-adrenoreceptors, uncoupling of beta-adrenoreceptors and adenylate cyclase, as well as modifications of downstream cAMP-mediated signaling. In compensated cardiac hypertrophy, these changes are associated with preserved or even enhanced basal ventricular systolic function due to increased sarcoplasmic reticulum Ca(2+) content and Ca(2+)-induced sarcoplasmic reticulum Ca(2+) release. The increased availability of Ca(2+) to maintain cardiomyocyte contraction is attributed to prolongation of the action potential due to inhibition of the transient outward potassium current as well as stimulation of the reverse mode of the Na(+)-Ca(2+) exchange. Further progression of cardiac hypertrophy towards heart failure is due to abnormalities in Ca(2+) handling, necrotic myocardial injury, and increased myocardial stiffness due to interstitial fibrosis.
Related Concept Videos
Heart Failure II: Pathophysiology
Antihypertensive Drugs: Action of β1 Blockers
Cellular Adaptation II: Hypertrophy
Pathophysiology of Heart Failure
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
